Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15492773 | 1.00 | PPARG (0.50) | PPARGCRBNPPARDPPARANPC1 | |
| SCHEMBL7004191 | 0.85 | CRBN (0.55) | CRBNNPC1PDE4APDE4BPDE4C | |
| SCHEMBL7005119 | 0.85 | CRBN (0.55) | CRBNNPC1PDE4APDE4BPDE4C | |
| SCHEMBL7057736 | 0.80 | ADRA1A (0.56) | CRBNADRA1APDE4APDE4BPDE4C | |
| SCHEMBL24461308 | 0.79 | GRIN1 (0.50) | NPC1 | |
| SCHEMBL7005602 | 0.78 | PDE4A (0.48) | PPARGCRBNNPC1PDE4APDE4B | |
| SCHEMBL7003587 | 0.77 | PDE4A (0.47) | PPARGCRBNNPC1PDE4APDE4B | |
| SCHEMBL15492780 | 0.77 | PDE4A (0.47) | PPARGCRBNNPC1PDE4APDE4B | |
| SCHEMBL17996701 | 0.77 | CRBN (0.52) | CRBNNPC1HRH3 | |
| SCHEMBL9392309 | 0.76 | HTT (0.47) | PPARGPPARDPPARANPC1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133140-B2 | Cycloalkylamne derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | MARUMOTO SHINJI (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-2341044-A1 | CYCLOALKYLAMINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010021351-A1 | CYCLOALKYLAMINE DERIVATIVE | 第一三共株式会社 (JP) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | PPARG 574/4885CRBN 1783/4885PPARD 281/4885 |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | PPARG 574/4885CRBN 1783/4885PPARD 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.